1. Home
  2. YDKG vs PCSA Comparison

YDKG vs PCSA Comparison

Compare YDKG & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDKG

Yueda Digital Holding Class A Ordinary Share

N/A

Current Price

$0.87

Market Cap

5.3M

ML Signal

N/A

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.11

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDKG
PCSA
Founded
2005
2011
Country
China
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
6.1M
IPO Year
2007
2012

Fundamental Metrics

Financial Performance
Metric
YDKG
PCSA
Price
$0.87
$2.11
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
11.8K
30.3K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.11
52 Week High
$3.90
$8.88

Technical Indicators

Market Signals
Indicator
YDKG
PCSA
Relative Strength Index (RSI) 36.67 39.70
Support Level $0.81 $1.76
Resistance Level $1.03 $2.33
Average True Range (ATR) 0.07 0.12
MACD -0.02 -0.01
Stochastic Oscillator 20.34 26.09

Price Performance

Historical Comparison
YDKG
PCSA

About YDKG Yueda Digital Holding Class A Ordinary Share

Yueda Digital Holding is a Web3 and digital company with a focus on the long-term accumulation of mainstream cryptocurrencies. The business activities of the company include active treasury management of mainstream digital assets, exploration of compliant, risk-managed yield opportunities, such as staking, on-chain liquidity provision, and other conservative market activities, selective investments and partnerships in Web3 infrastructure and applications, and advisory services for enterprises entering the digital-asset economy.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.

Share on Social Networks: